Here's some of what is coming soon to NeurologyLive® this week.
Feature|Articles|December 5, 2024
System Integration: How AI Is Weaving Itself into Neurology
Author(s)Marco Meglio
Perspective from neurologists on the current and future applications for artificial intelligence across a bevy of neurologic conditions.
Advertisement
Advertisement
Artificial intelligence (AI) refers to the use of computer systems or machines to simulate human intelligence processes such as learning, reasoning, problem-solving, and decision-making. AI systems often rely on algorithms, data analysis, and machine learning to identify patterns and perform tasks that traditionally require human input. AI technologies include natural language processing, computer vision, robotics, neural networks, and machine learning, among others.
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 25, 2026.
The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.
FDA approves once-daily oral tavapadon for Parkinson disease, a first-in-class D1/D5 partial agonist that improves motor function and ON time, with key safety warnings.
Early phase 1 findings showed that the PROTAC LRRK2 degrader ARV-102 was associated with improvements in saccadic hypometria and changes in CSF markers of endolysosomal function, neuroinflammation, synaptic integrity, and axonal guidance in participants with Parkinson disease.
Full results from the phase 2b LUMA showed that investigational BIIB122/DNL151 did not slow confirmed clinical worsening in early-stage Parkinson's disease compared with placebo.
Advertisement
Advertisement